TACR1 and infection: For example, an NK-1R antagonist has been shown to prevent seizure activity in a rodent model of helminth brain infection [32], while our own studies have shown that pharmacological targeting of NK-1R with the antagonist L703,606 can not only prevent the development of damaging inflammation due to streptococcal CNS infection when administered prophylactically but can also reverse infection-associated gliosis and demyelination when delivered therapeutically without increasing CNS bacterial burden [8].